We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

CADx System Combines AI with Low-Cost MRI Scans to Speed up Prostate Cancer Detection

By MedImaging International staff writers
Posted on 29 Mar 2023
Print article
Image: New AI tool can safely delay, as well as inexpensively and accurately monitor prostate cancer treatment (Photo courtesy of Bot Image)
Image: New AI tool can safely delay, as well as inexpensively and accurately monitor prostate cancer treatment (Photo courtesy of Bot Image)

The current protocol for treating prostate cancer involves a number of uncomfortable and unreliable procedures. One example is the PSA test, which measures the level of prostate-specific antigen (PSA) in the blood and can sometimes indicate the presence of prostate cancer. However, this test is not conclusive and often leads to additional testing such as MRI to identify any abnormalities in the prostate. The development of new blood, urine or tissue tests for prostate cancer could be very promising but such tests do not reveal the location or extent of the cancer, which is something that imaging with artificial intelligence (AI) can do.

Similarly, digital rectal exams (DREs) have been found to be just slightly over 50% accurate due to the significant number of prostate cancers located in the anterior aspect of the gland, which is far from the rectum and cannot be felt. In addition, while biopsies can confirm the presence of cancer, their random or targeted sampling often miss cancerous lesions. Biopsies are also costly, carry a risk of infection, and can lead to false positives. Therefore, biopsies are not an effective screening method for prostate cancer but can confirm a diagnosis if used in conjunction with imaging guidance. Now, a powerful computer-aided diagnosis (CADx) software device is poised to change the standard of care for prostate cancer screening, detection and diagnosis by avoiding the expensive pitfalls of current prostate cancer pathways.

The ProstatID AI software from Bot Image, Inc. (Omaha, NE, USA) is not only intended for cancer detection and diagnosis but also for prostate cancer screening using MRI and a non-invasive/non-contrast "short-form" of MRI sequences known as bi-parametric MRI (bpMRI). bpMRI eliminates the need for expensive, time-consuming contrast agents that can damage the kidneys, thereby facilitating a low cost and easily accessible MRI. Bot Image's Prostate AI has enormous implications for men's health and healthcare cost savings, as it is a highly accurate tool for active surveillance. This means that periodic low-cost MRI scans supplemented with the AI interpretation of ProstatID can be conducted, resulting in significant savings.

In clinical trials conducted by Bot Image, the algorithm performed with 93.6% accuracy when used on its own (with area under the sensitivity-specificity curve). Additionally, physician performance was considerably enhanced. In comparison, no other screening method comes close to matching ProstatID's level of sensitivity, specificity, and ability to locate and determine the extent of cancer. ProstatID has been developed using thousands of proprietary MR image sets, radiologist interpretations, segmented prostate gland image sets, pathology laboratory results, correlation data, and initial AI interpretations to aid in the early diagnosis of prostate cancer. Bot Image has received FDA-clearance for its ProstatID AI software for cancer detection and diagnosis, as well as for prostate cancer screening using MRI and bpMRI.

Related Links:
Bot Image, Inc.

Gold Supplier
Ultrasound Phantom
Multi-Purpose Multi-Tissue Ultrasound Phantom - Model 040GSE
New
SPECT/CT Scanner
AnyScan SC
New
Dose Area Product Measuring System
VacuDAP duo
New
Mobile X-Ray Unit
Exairo Plus

Print article
FIME - Informa
Sun Nuclear -    Mirion

Channels

Radiography

view channel
Image: BiOI ruby-like crystals can improve medical imaging safety by lowering intensities of harmful X-rays (Photo courtesy of University of Cambridge)

Sustainable Solar Cell Material Could Revolutionize Medical Imaging

The use of X-rays for internal body imaging has dramatically changed non-invasive medical diagnostics. Yet, the high dose of X-rays required for these imaging techniques, due to the poor performance of... Read more

Ultrasound

view channel
Image: A novel, skull-implantable ultrasound device can open the blood-brain barrier to deliver chemotherapy (Photo courtesy of Northwestern Medicine)

Skull-Implantable Ultrasound Device Enables Powerful Chemotherapy Drug to Reach Brain Tumors

A significant challenge in treating lethal brain cancer known as glioblastoma has been the inability of powerful chemotherapy to penetrate the blood-brain barrier to target the aggressive brain tumor.... Read more

Nuclear Medicine

view channel
Image: The components of the dosimeter can fit into an 18mm by 7mm capsule (Photo courtesy of University of NUS)

Novel Ingestible Capsule X-Ray Dosimeter Enables Real-Time Radiotherapy Monitoring

Gastric cancer ranks among the most prevalent cancers worldwide. Precision is vital in modern radiotherapy, as it aims to target tumor cells while minimizing damage to healthy tissue. However, challenges... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The global AI-enabled medical imaging solutions market is expected to reach USD 18.36 billion in 2032 (Photo courtesy of Freepik)

Global AI-Enabled Medical Imaging Solutions Market Driven by Need for Early Disease Detection

The AI-enabled medical imaging solutions market is currently in its developmental stages, following the significant role of AI-based tools in combating the COVID-19 pandemic. The pandemic saw an upswing... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.